title: Progress in the development of vaccines for hepatitis C virus infection.
abstract: The hepatitis C virus (HCV), first described in 1989, is now a leading cause of liver cirrhosis and hepatocellular carcinoma. With more than 170 million people infected globally, this virus is a major public health issue. The current standard therapy is based on interferon in combination with ribavirin. This costly therapy often fails to completely clear the infection and is associated with adverse side effects. Recent anti-HCV therapies are interferon-free direct-acting antiviral (DAA) regimens for HCV, including simeprevir, sofosbuvir, and ledipasvir, which have effects on non-structural proteins. DAA regimens have several advantages, such as specifically targeting HCV viral replication, accompanied by very high sustained virological response rates and lower side effects like flu-like syndrome. These facts plus the fact that most HCV cases progress to chronic infection suggest the potential need for an efficient HCV vaccine. Different innovative methods, including methods based on peptide, recombinant protein, DNA, vector-based, and virus-like particles, have been introduced for the development of HCV vaccines. An extensive number of studies have been published on these vaccines, and some vaccines were even tested in clinical trials. In the current review, progress in the development of preventive and therapeutic vaccines against the HCV is reviewed in the context of peptide vaccines, recombinant protein vaccines, HCV-like particle, DNA vaccines and viral vectors expressing HCV genes.
authors.affiliation: Faezeh Ghasemi, Department of New Sciences and Technology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad 9196773117, Iran.
authors.forename: Faezeh
authors.initials: F
authors.lastname: Ghasemi
authors.affiliation: Faezeh Ghasemi, Department of New Sciences and Technology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad 9196773117, Iran.
authors.forename: Sina
authors.initials: S
authors.lastname: Rostami
authors.affiliation: Faezeh Ghasemi, Department of New Sciences and Technology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad 9196773117, Iran.
authors.forename: Zahra
authors.initials: Z
authors.lastname: Meshkat
mesh_terms: D000818:Animals; D055808:Drug Discovery / Q000379:methods*; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity; D006526:Hepatitis C / Q000175:diagnosis / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D054884:Host-Pathogen Interactions; D006801:Humans; D007114:Immunization; D010641:Phenotype; D014761:Viral Hepatitis Vaccines / Q000276:immunology / Q000627:therapeutic use*
chemical_list: D014761:Viral Hepatitis Vaccines
keywords: Hepatitis C virus; Hepatitis C virus infection; Preventive vaccine; Therapeutic vaccine